2. PI3K/Akt/mTOR Stem Cell/Wnt NF-κB Neuronal Signaling
  3. GSK-3 NF-κB Amyloid-β
  4. Cromolyn disodium

Cromolyn disodium  (Synonyms: Cromoglycate disodium; Cromoglicic acid disodium; FPL-670)

Cat. No.: HY-B0320A Purity: 99.93%
SDS
COA
Handling Instructions Technical Support

Cromolyn (Cromoglycate) disodium is an orally active GSK-3β inhibitor with an IC50 of 2.0 μM. Cromolyn disodium is also a mast cell stabilizer that can inhibit the release of mediators from mast cells, regulate reflex bronchoconstriction, and reduce non-specific bronchial hyperreactivity, and Cromolyn disodium can be used in the research of bronchial asthma. In addition, Cromolyn disodium has multiple activities such as anti-inflammatory, anti-allergic, anti-histamine, anti-cancer, and neuroprotective effects.

For research use only. We do not sell to patients.

Cromolyn disodium Chemical Structure

Cromolyn disodium Chemical Structure

CAS No. : 15826-37-6

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
500 mg In-stock
1 g In-stock
5 g In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 6 publication(s) in Google Scholar

Other Forms of Cromolyn disodium:

Cromolyn disodium Related Antibodies

Top Publications Citing Use of Products

    Cromolyn disodium purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2017 Nov;125(Pt B):150-160.  [Abstract]

    The IL-33 production in different treatment groups is determined in rat skin by immunohistochemistry assay.

    View All GSK-3 Isoform Specific Products:

    View All Isoforms
    GSK-3 GSK-3α GSK-3β

    View All NF-κB Isoform Specific Products:

    View All Isoforms
    NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Cromolyn (Cromoglycate) disodium is an orally active GSK-3β inhibitor with an IC50 of 2.0 μM. Cromolyn disodium is also a mast cell stabilizer that can inhibit the release of mediators from mast cells, regulate reflex bronchoconstriction, and reduce non-specific bronchial hyperreactivity, and Cromolyn disodium can be used in the research of bronchial asthma. In addition, Cromolyn disodium has multiple activities such as anti-inflammatory, anti-allergic, anti-histamine, anti-cancer, and neuroprotective effects[1][2][3][4][5].

    Cellular Effect
    Cell Line Type Value Description References
    CHO EC50
    0.986 μM
    Compound: 2
    Agonist activity at rat GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay
    Agonist activity at rat GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay
    		[PMID: 23713606]
    CHO EC50
    1.26 μM
    Compound: 2
    Agonist activity at human GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay
    Agonist activity at human GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay
    		[PMID: 23713606]
    CHO EC50
    4.84 μM
    Compound: 2
    Agonist activity at mouse GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay
    Agonist activity at mouse GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay
    		[PMID: 23713606]
    LAD2 IC50
    > 1 mM
    Compound: DSCG
    Inhibition of human LAD2 mast cell activation assessed as compound 48/80-induced degranulation incubated for 30 mins prior to compound 48/80 challenge by beta-hexosaminidase release assay
    Inhibition of human LAD2 mast cell activation assessed as compound 48/80-induced degranulation incubated for 30 mins prior to compound 48/80 challenge by beta-hexosaminidase release assay
    		[PMID: 23617679]
    Mast cell ED50
    2.55 μg/mL
    Compound: disodium cromoglycate
    Antianaphylactic activity in rat mast cells assessed as inhibition of DNP-ovalbumin-induced histamine release after 15 mins by superfusion assay
    Antianaphylactic activity in rat mast cells assessed as inhibition of DNP-ovalbumin-induced histamine release after 15 mins by superfusion assay
    		[PMID: 82617]
    Mast cell IC50
    6.5 μM
    Compound: cromolyn sodium
    Antiallergic activity in rat peritoneal mast cells assessed as inhibition of ovalbumin-induced histamine release after 15 mins
    Antiallergic activity in rat peritoneal mast cells assessed as inhibition of ovalbumin-induced histamine release after 15 mins
    		[PMID: 88523]
    RBL-2H3 IC50
    1540 μM
    Compound: DSCG
    Antihistaminic activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced beta-hexosaminidase release preincubated for 10 mins before DNP-BSA challenge
    Antihistaminic activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced beta-hexosaminidase release preincubated for 10 mins before DNP-BSA challenge
    		[PMID: 14510616]
    In Vitro

    Cromolyn (0-100 μM; 3-10 min) disodium can inhibit IgE- and antigen-induced degranulation and PGD2 synthesis in rat peritoneal mast cells[1].
    Cromolyn (0-100 μM; 0-72 h) disodium can block S100P-promoted cell proliferation, invasion, and increased NF-κB activity in Panc-1 cells[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Cromolyn disodium Related Antibodies
    In Vivo

    Cromolyn (10 mg/kg; intravenous injection; single dose) disodium can significantly inhibit mast cell activation in IgE-dependent PCA by reducing Evans blue extravasation and completely inhibit antigen-induced plasma histamine increase in PSA in rats[1].
    Cromolyn (5 mg/kg; intraperitoneal injection; 5 weeks) disodium has anti-tumor activity in a mouse model of pancreatic cancer[2].
    Cromolyn (6.3 mg/kg; intraperitoneal injection; 5 times a week; from postnatal day 60 until euthanasia) disodium has an ameliorative effect in a model of amyotrophic lateral sclerosis[3].
    Cromolyn (1-3.15 mg/kg; intraperitoneal injection; 3 times a week; 12 weeks) disodium has a neuroprotective effect in a mouse model of Alzheimer's disease[4].
    Cromolyn (1.43-5.72 mg/kg; intraperitoneal injection; 1 month) disodium has a hypoglycemic effect in mice[5].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Male CB17 scid mice aged 4 weeks old treated BxPC-3 and MPanc-96 cells[2]
    Dosage: 5 mg/kg
    Administration: Intraperitoneal injection; 5 weeks
    Result: Significantly reduced tumor burden.
    Reduced lung metastasis in the BxPC-3 model and both liver and lung metastases in the MPanc-96 model.
    Had no effect on body weight.
    Animal Model: SOD1G93A mice[3]
    Dosage: 6.3 mg/kg
    Administration: Intraperitoneal injection; 5 times a week; from postnatal day 60 until euthanasia
    Result: Delays disease onset.
    Improved motor deficits in the PaGE task.
    Increased survival of lumbar spinal cord motor neurons, decreased denervation at the neuromuscular junction.
    Reduced pro-inflammatory cytokine and chemokine levels in the spinal cord and plasma.
    Decreased mast cell degranulation in the tibialis anterior muscle.
    Animal Model: APPSwedish expressing Tg2576 mice[4]
    Dosage: 1 and 3.15 mg/kg
    Administration: Intraperitoneal injection; 3 times a week; 12 weeks
    Result: Reduced the levels of Aβ40 and Aβ42 in brain TBS-insoluble fractions.
    Increased the level of Aβ38.
    Promoted the phagocytosis of β-amyloid by microglia.
    Animal Model: Normal Balb/c mice, chronic type II diabetic Balb/c mice, and chronic obese Balb/c mice[5]
    Dosage: 1.43, 2.86 and 5.72 mg/kg
    Administration: Intraperitoneal injection; 1 month
    Result: Dose-dependently reducted blood glucose, body weight, and resistin levels.
    Increased liver glycogen, insulin, C-peptide, and adiponectin levels in mice.
    Clinical Trial
    Molecular Weight

    512.33

    Formula

    C23H14Na2O11
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    OC(COC1=C2C(C=C(C(O[Na])=O)OC2=CC=C1)=O)COC3=C4C(C=C(C(O[Na])=O)OC4=CC=C3)=O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, protect from light, stored under nitrogen

    *In solvent : -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen)

    Solvent & Solubility
    In Vitro: 

    H2O : 50 mg/mL (97.59 mM; Need ultrasonic)

    DMSO : 25 mg/mL (48.80 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.9519 mL 9.7593 mL 19.5187 mL
    5 mM 0.3904 mL 1.9519 mL 3.9037 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (4.88 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (4.88 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 50 mg/mL (97.59 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Purity & Documentation

    Purity: 99.93%

    SDS (393 KB)

    COA (247 KB) LCMS (94 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO / H2O 1 mM 1.9519 mL 9.7593 mL 19.5187 mL 48.7967 mL
    5 mM 0.3904 mL 1.9519 mL 3.9037 mL 9.7593 mL
    10 mM 0.1952 mL 0.9759 mL 1.9519 mL 4.8797 mL
    15 mM 0.1301 mL 0.6506 mL 1.3012 mL 3.2531 mL
    20 mM 0.0976 mL 0.4880 mL 0.9759 mL 2.4398 mL
    25 mM 0.0781 mL 0.3904 mL 0.7807 mL 1.9519 mL
    30 mM 0.0651 mL 0.3253 mL 0.6506 mL 1.6266 mL
    40 mM 0.0488 mL 0.2440 mL 0.4880 mL 1.2199 mL
    H2O 50 mM 0.0390 mL 0.1952 mL 0.3904 mL 0.9759 mL
    60 mM 0.0325 mL 0.1627 mL 0.3253 mL 0.8133 mL
    80 mM 0.0244 mL 0.1220 mL 0.2440 mL 0.6100 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Cromolyn disodium Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Cromolyn disodium15826-37-6Cromoglycate disodiumCromoglicic acid disodium FPL-670FPL670FPL 670FPL-670GSK-3NF-κBAmyloid-βGlycogen synthase kinase-3Glycogen synthase kinase 3Nuclear factor-κBNuclear factor-kappaBβ-amyloid peptideAβAbetapancreatic cancer modelamyotrophic lateral sclerosis modelAlzheimer's disease modelrat peritoneal mast cellsPanc-1 cellsInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Cromolyn disodium
    Cat. No.:
    HY-B0320A
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.